CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Core Insights - Casgevy, the gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $54 million in Q4 revenue and $116 million for the full year, with 64 patients receiving infusions in 2025, including 30 in Q4 [1] - The initiation of treatment for 147 patients globally in 2025 nearly tripled compared to 2024, indicating strong momentum heading into 2026 [1][2] - William Blair analysts express confidence that the increase in first cell collections will lead to significantly higher revenue in 2026 [2] - The company is advancing its in vivo liver editing programs, with CTX310 in Phase 1b trials for lipid disorders and CTX321 progressing through enabling studies, with updates expected in H2 2026 [2] - The siRNA-based candidate CTX611 is in Phase 2 trials for knee replacement surgery patients and may have broader applications in thromboembolic diseases [3] - CRISPR Therapeutics ended 2025 with $1.98 billion in cash and marketable securities, while R&D expenses rose to $83.5 million in Q4, and the net loss widened to $130.6 million from $37.3 million a year earlier [4] - CRISPR Therapeutics shares increased by 8.81% to $53.24 at the time of publication [4]